Market: NASD |
Currency: USD
Address: 3963 Maple Avenue
Instil Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing a pipeline of novel therapies. The company develops cell therapy of tumor infiltrating lymphocyte (TIL) for the treatment of cancer. It is developing early-stage pipeline of CoStAR-TIL and other novel TIL technologies. Instil Bio, Inc. was incorporated in 2018 and is headquartered in Dallas, Texas.
📈 Instil Bio, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$118.67
-
Upside/Downside from Analyst Target:
339.51%
-
Broker Call:
5
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2025-11-13
-
EPS Estimate:
-3.04
💰 Dividend History
| Year |
Annual Yield (%) |
Total Amount |
Current Yield (%) |
Ex Date |
Pay Date |
Particulars |
| 2023 |
- |
$0.050000 |
- |
2023-12-08 |
- |
Stock split |
|
Total Amount for 2023: $0.050000 |
📅 Earnings & EPS History for Instil Bio, Inc.
| Date | Reported EPS |
|---|
| 2025-11-13 (estimated upcoming) | - |
| 2025-08-13 | -2.88 |
| 2025-05-13 | -4.32 |
| 2025-03-04 | -1.08 |
| 2024-11-13 | -2.55 |
| 2024-08-13 | -1.57 |
| 2024-05-10 | -2.39 |
| 2024-03-21 | -1.26 |
| 2023-11-13 | -3.2 |
| 2023-08-14 | -2.2 |
| 2023-05-11 | -5 |
| 2023-03-31 | -8.2 |
| 2022-11-14 | -8.6 |
| 2022-08-12 | -9.2 |
| 2022-05-16 | -8.4 |
| 2022-03-07 | -9 |
| 2021-11-15 | -6.6 |
| 2021-08-12 | -5.4 |
| 2021-05-13 | -13.2 |
📰 Related News & Research
No related articles found for "instil bio".
